Unbiased AI-powered news
8 stories related to this topic, newest first.
ibtimes.co.ukPanelists at the STAT Breakthrough West 2026 conference shared views on expanding access to medical innovation and improving patient-focused healthcare and reporting.
The Japan TimesAn advisory panel to the health minister approved Sumitomo Pharma’s Amchepry on May 13, 2026, making it the world's first commercialized medical product derived from iPS cells. The treatment, costing ¥55.3 million ($350,600) per patient, will gain insurance coverage on May 20 wit…
vancouversun.comDiagnosed with Stage II breast cancer at 29, Maralee Lellio later faced terminal Stage IV disease that spread to her brain. After aggressive treatment including a PARP inhibitor matched to her BRCA-1 positive cancer, she achieved two years cancer-free, paused medication and conce…
Rwanda's health minister met with a delegation from Cleveland Clinic and U.S. embassy representatives to discuss a potential partnership. The talks focused on medical innovation, research and healthcare development. Cleveland Clinic is a nonprofit academic medical center that ope…
South China Morning PostResearchers at the University of Hong Kong have created a nasal spray that delivers neurotherapeutic powder to the brain for ischemic stroke patients. The innovation, called NanoPowder, won the Special Grand Prize and a gold medal at the 51st International Exhibition of Invention…
BloombergDoctors in Australia's outback are testing mobile brain scanners capable of distinguishing clots from bleeds. These devices provide results in minutes. The testing aims to improve stroke care in remote areas.
Los Angeles TimesRecent snakebite fatalities in California have drawn attention to efforts to develop an oral antivenom pill. Ophirex is advancing Varespladib, a treatment designed to improve survival odds after bites from common U.S. snakes. The pill is intended for immediate use before hospital…
Substrate placeholder — needs reviewCAR-T cell therapy, originally developed for cancer treatment, is achieving more remissions in patients with autoimmune diseases. According to STAT News, this progress has prompted additional clinical trials and investments from pharmaceutical companies.